CN109715197A - Collagenic hydrolysate is used to improve the purposes of endurance performance and stimulation lipid catabolism - Google Patents

Collagenic hydrolysate is used to improve the purposes of endurance performance and stimulation lipid catabolism Download PDF

Info

Publication number
CN109715197A
CN109715197A CN201780053530.4A CN201780053530A CN109715197A CN 109715197 A CN109715197 A CN 109715197A CN 201780053530 A CN201780053530 A CN 201780053530A CN 109715197 A CN109715197 A CN 109715197A
Authority
CN
China
Prior art keywords
purposes
hydrolysate
collagenic
collagenic hydrolysate
daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780053530.4A
Other languages
Chinese (zh)
Inventor
斯特芬·奥瑟尔
斯特凡·豪斯曼斯
汉斯-乌尔里希·弗雷希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galida Co Ltd
Gelita AG
Original Assignee
Galida Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102017102873.0A external-priority patent/DE102017102873A1/en
Application filed by Galida Co Ltd filed Critical Galida Co Ltd
Publication of CN109715197A publication Critical patent/CN109715197A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A61K8/355—Quinones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/592—Mixtures of compounds complementing their respective functions
    • A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Birds (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)

Abstract

It is used to improve the purposes of endurance performance by increasing mitochondria activity the present invention relates to collagenic hydrolysate.It is used to stimulate lipid catabolism by increasing mitochondria activity the invention further relates to collagenic hydrolysate, the purposes especially lost weight.

Description

Collagenic hydrolysate is used to improve the purposes of endurance performance and stimulation lipid catabolism
The present invention relates to the purposes that collagenic hydrolysate is used to improve endurance performance.
In addition, being used to stimulate lipid catabolism the present invention relates to collagenic hydrolysate, especially for reducing weight Purposes.
Collagenic hydrolysate, especially by the starting material of the animal origin comprising collagen enzymatic hydrolysis generate, be by Peptide mixer composition, the molecular weight of the peptide depends on starting material and working condition and has dividing for certain size range Cloth.Collagenic hydrolysate as nutritional supplement purposes it is known to the public have the comparable time, especially for prevent and/ Or treatment bone, joint or connective tissue disease, especially because having been proven that collagen peptide for the body in these organization types The synthesis that body has extracellular matrix by oneself has stimulation (see, for example, Bello et al., Curr.Med.Res.Opin.2006 (22)2221-2232)。
It has now surprisingly been found that, collagenic hydrolysate also causes the active enhancing of humans and animals cell Mitochondria, that is, draws Play the increase of the mitochondria number of each cell and/or the increase of individual mitochondria.
From this discovery it is found that collagenic hydrolysate of the invention can be used in a manner of targeting, increase for passing through Mitochondria activity in the myocyte of humans and animals and improve endurance performance and stimulation lipid catabolism in humans and animals.
The endurance of human or animal's body shows and is used for ATP (atriphos) required for muscle systems supply for a long time The ability of the aerobic metabolism of the energy of form is related.One key factor of aerobic capacity is the absorption of oxygen, again by three A factor determines: utilizing by the oxygen supply of lung, by the oxygen transport of cardiovascular system and the oxygen in myocyte.Although maximum Oxygen-supplying amount is substantially predefined by the anatomic environment (total surface area of alveolar) of individual, but can be by trained and other Measure improves oxygen transport and oxygen utilizes, wherein the last one described step has typically represented conclusive limiting factor.Therefore, Endurance, which shows, relies basically on (each myocyte's, or in entire muscle systems) mitochondria number, in respiratory chain Consumption oxygen and the reaction for generating ATP occur in mitochondria.
In general, the increase of mitochondria activity means that the metabolic rate of body improves, and have per unit time a greater amount of Nutrient be metabolized for energy regenerating.However, the activity of higher catabolism necessarily causes (if nutrition supply is kept It is constant) the more havoc of body reserve, that is, stimulation lipid catabolism.Herein, the long-chain carboxylic acid's class discharged from adipose tissue Catabolism occur in large quantities in entire body, particularly in liver, therefore, for improve endurance performance it is opposite It is not the mitochondria only related in myocyte for this aspect of the invention.
The purposes of collagenic hydrolysate of the invention especially includes non-therapeutic use, that is, is administered to collagenic hydrolysate Do not need medically endurance performance or weight in terms for the treatment of human or animal.On the contrary, the purpose of the purposes one side is It typically would be desirable to endurance performance enhancing.This can contribute to improve quality of life, especially related with the people to be keen on sports.Separately On the one hand, due to stimulation lipid catabolism caused by weight loss may mainly due to cosmetic reasons and cater to the need, that is, Improve Body proportion.
However, in addition to this, the invention also includes collagenic hydrolysates for preventing and/or treating to be characterized in that mitochondria The therapeutic use for the pathological conditions that activity reduces.In particular, the pathological conditions can with endurance show reduce and/ Or weight gain is characterized.
In the case where this therapeutic use, the pathological conditions are preferably selected from obesity, cardiovascular disease, the rhythm of the heart Uneven, cardiac insufficiency, hypotony, hypertension, metabolic disorder, diabetes, metabolic syndrome, abrasive grit cellulous anemia, kidney With the dysfunction of liver, neuropathy, incoordination, epileptic attack, dementia, Alzheimer's disease, autism, depression, slow Fatigue syndrome, Parkinson's disease, motor neuron disease, multiple sclerosis, apoplexy sample symptom, migraine, myoclonia, fiber crops Numbness, neuralgia, hyperalgia, hyperesthesia, dysphagia, vomiting, constipation, diarrhea, optic nerve fiber and retina denaturation, Nystagmus, ptosis, yctalopia, hearing loss, deafness and inner ear disorders.For these indications, increase can be passed through Mitochondria number improves mitochondria activity realization therapeutic effect.
Because the increase of mitochondria activity declines glucose level, the application of collagenic hydrolysate also to prevention and/or Treating cancer, i.e. malignant tumour, there is good effect.This be based on following observation as a result, i.e. tumour cell mainly pass through it is scarce Oxygen metabolism (lactic fermentation) supplies energy required for them, and is therefore necessarily dependent on glucose.Therefore, soma Higher glucose consumption can weaken tumour cell.
In the case where the present invention, it was found that the protein kinase (AMPK) that collagenic hydrolysate causes enzyme AMP- to activate is more Height expression.This adjusting enzyme equally has an impact to the energetic supersession of cell, so, increase AMPK quantity also to endurance performance and rouge Matter catabolism has positive effect.The mitochondria activity caused by collagenic hydrolysate increases may between AMPK expression increase There are direct correlations.
All use of the invention on the way, collagenic hydrolysate is preferably applied through enteron aisle, is especially administered orally.
In a preferred embodiment of the invention, collagenic hydrolysate is applied in the form of nutritional supplement.It is especially advantageous , apply the form in the form of a solution for example as the bottle of preparation and carry out or carry out in powder form.Since it is good Solubility, collagenic hydrolysate can also be added in different beverages without causing muddiness.Collagen water tasteless The receiving that user can be improved in the application of solution product is horizontal.
Preferred embodiment according to the invention, other than collagenic hydrolysate, the nutritional supplement is without in addition Protein or protein hydrolysate.It is formed in the nutritional supplement kept with muscle, is used for muscle known Various protein, the people to be especially keen on sports, the purpose is to largely replace carbohydrate and rouge by protein Fat is as energy supply object.However, purposes of the invention is not based on function of the collagenic hydrolysate as energy supply, but Based on the above-mentioned specific function to mitochondria activity.
Therefore, in another embodiment of the present invention, other than collagenic hydrolysate, the nutritional supplement is not Containing other physiologically active component.
However, optionally, the present invention also includes using collagenic hydrolysate as the (battalion with a variety of other components Support) component of enriching substance is come the case where application.Specifically, collagenic hydrolysate can be added to food or snacks is for example skilful Gram force stick, protein rod or cereal bars (so-called functional food)；Or milk, dairy products (such as Yoghourt) and milk replacer (example Such as soya-bean milk, almond milk and coconut milk) in.
No matter apply in what manner, collagenic hydrolysate is more excellent typically with daily 1-40g, preferably daily 2.5-30g Select daily 10-25g, the amount application of especially daily 12.5-20g.
In collagenic hydrolysate not as unique physiologically active group timesharing of nutritional supplement, for use of the invention For way, it can for general health and be especially presented with other components of positive effect with one or more to endurance It is combined.Such component be preferably selected from vitamin C, vitamin B, D, E and K series, conjugated linoleic acid, caffeine and its Derivative, Guarana extract, green-tea extract, Epigallo-catechin gallate (EGCG), creatine, L-BETAIN, L- melon ammonia Acid, L-arginine, alpha-lipoic acid, N-acetylcystein, NADH, D-ribose, magnesium aminosuccinate, antioxidant such as anthocyanidin, Carotenoid, flavonoids, resveratrol, glutathione, superoxide dismutase and xanthone such as mangiferin, minerals are such as Iron, magnesium, calcium, zinc, selenium and phosphorus and other oroteins, hydrolysate or peptide such as soybean, wheat or lactalbumin.
Another advantageous embodiment of the invention is related to collagenic hydrolysate and 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone and/or panthenol --- That is ubiquinone10Oxidation and reduction form combination, wherein due to panthenol better bioavilability and it is preferred that panthenol.Even if making With the daily intaking amount of 50-100mg panthenol, the positive effect for physical efficiency is also observed, presumption is the antioxidation pair of panthenol The promotion of mitochondria activity.In this way, collagenic hydrolysate is in the above-mentioned indication with mitochondria dysfunction Effect is supported.Alternatively or additionally, it is also possible for combining collagenic hydrolysate with pyrroloquinoline quinone (PQQ), PQQ is found to be a kind of important redox confactor recently.
In one embodiment of the invention, by the application of collagenic hydrolysate and endurance training or altitutde training It is combined.The aerobic capacity of metabolism can be improved in endurance training.It is also known that in environment of the oxygen with respect to reduction In physical training (hypoxic training) remarkable effect is presented with to endurance, so, while being applied using the dosage of collagenic hydrolysate With, can correspondingly be expected synergistic effect.This is especially significant for the people to be keen on sports.
On the other hand, within the scope of the present invention, applied in the case where no endurance training, altitutde training or muscular training Collagenic hydrolysate is equally possible and actually useful.In particular, showing in animal experiment (seeing below) The influence having been observed that Ben Faming to mitochondria activity etc. is combined with normal body movement.
According to the present invention, the molecular weight of the collagenic hydrolysate used can change in a wide range, wherein the upper limit by Collagenic hydrolysate has sufficiently high hydrolysis degree not at room temperature to be gelled and to provide for water solubility, this and denaturation Collagen or gelatin are different.The soluble peptide of collagenic hydrolysate can be fully subsequently reabsorbed into body.Typically, collagen water The average molecular weight that product has 200-25000Da is solved, preferably 1000-6000Da, more preferable 1200-4000Da are even more excellent Select 1500-3500Da, especially 2800-3300Da.
Advantageously, producing collagenic hydrolysate by the way that enzymatic hydrolysis includes the starting material of collagen.For the hydrolysis, Especially using microorganism or the endopeptidase and/or exopeptidase of plant origin.
The starting material comprising collagen is typically chosen from the skin or bone of vertebrate, preferably mammal, especially The skin (ox-hide or pigskin) of ox or pig.Can be from these starting materials with One-step production collagenic hydrolysate, or it can be through The intermediate stage of gelatin is spent, in this case, type A gelatin and type B gelatin can be used.
As alternative, the collagenic hydrolysate for purposes of the present invention can be produced by recombinant gene expression. By using natural collagen sequence, collagen sequence especially from ox or pig and its gene modification cell (for example, Yeast, bacterium or plant cell, especially tobacco cell) in expression, the product of production can be with corresponding comprising collagen The hydrolysate of raw material is substantially the same.Herein, it is possible to obtain relatively narrow or precisely predetermined molecular weight distribution.Make For alternative, the sequence can be changed by mutation, so that the special properties to product have an impact.
The invention further relates to for improving endurance performance and/or stimulation lipolytic generation by improving mitochondria activity The method thanked, particularly lost weight.The method preferably includes through enteron aisle, particularly collagen water is administered orally to human or animal Solve product.The method can be therapeutic method or actually non-therapeutic method.
The present invention is explained in greater detail with reference to the in vitro and in vivo experimental result described in the examples below.
In the accompanying drawings:
Fig. 1 shows the fluorescence microscope images for the SH-SY5Y cell cultivated in the presence of collagenic hydrolysate.
Embodiment
1. improving mitochondria number using collagenic hydrolysate
There is a possibility that showing collagenic hydrolysate in vitro with human nerve cell (Human Neuroblastoma Cell Line SH-SY5Y) For improving the validity of mitochondria number.
By SH-SY5Y cell 0.05 weight %, 0.2 weight % and 2.5 weight % with various concentration collagen water It solves and is cultivated in the culture medium of product.For this purpose, using the average molecular weight produced by enzymatic hydrolysis from pigskin gelatin in 3000Da The collagenic hydrolysate (hereinafter referred to as collagenic hydrolysate A) of left and right.Pass through point for the peptide that gel permeation chromatography measures Son amount distribution is shown in table 1 below:
Table 1: the molecular weight distribution of collagenic hydrolysate A
Fraction Weight %
>7500Da <10
3500–7500Da 20-30
1500–3500Da 30-33
500–1500Da 25-38
100–500Da <5
In order to direct estimation mitochondria number, mitochondrial protein ingredient TOM20 is subjected to fluorescent marker.TOM20 It is the subunit of one of mitochondrial outer membrane receptor complex, has and cytoplasmic precursor protein (propetide) is moved to line grain Function in body.There, the protein as the enzyme of respiratory chain or citrate cycle falls presequence by cracking and is activated.
As a result, under fluorescence microscope the quantity of the TOM20 of visible fluorescent marker be cell Mitochondria number amount Degree.It is shown with the cell of the collagenic hydrolysate culture of 0.05 weight %, 0.2 weight % and 2.5 weight % in Figure 1A, 1B and 1C In, wherein the clearly visible light fluorescence (being originally used for green) in nucleus (being originally used for blue) peripheral region is with concentration Increase and increases.Thus, collagenic hydrolysate increases SH-SY5Y cell Mitochondria number and thus makes total mitochondria living Property increase.
2. enzyme AMPK is by collagenic hydrolysate Activated in Vitro
The protein kinase (AMPK) of AMP- activation participates in the energy supply in both adipose tissue and muscle systems.Because AMP is formed when consuming ATP, the indicant of energy deficiency can be seen as.Thus, the expression of AMPK is activated from deposit Fat energy reserve and play a role in glycolytic cycle.
In order to determine influence that collagenic hydrolysate expresses AMPK, person monocytic cell is being included into 0.5mg/ml collagen water It solves and is cultivated 24 hours in the culture medium of product.After removing culture medium, RNA is extracted from cellular layer, and draw using specificity Object measures the amount of AMPK-RNA by PCR.
Compared with the control without collagenic hydrolysate, AMPK-RNA increases significantly (more than 600 times).Equally from this It was found that thus demonstrating the stimulation of energetic supersession of the collagenic hydrolysate to cell.
3. enzyme AMPK is activated in collagenic hydrolysate body
The positive effect for confirming that collagenic hydrolysate expresses AMPK in animal experiment body can also be used.
For this purpose, being equivalent to the collagenic hydrolysate of the amount of 10g people's equivalent dose for the daily feeding of mouse, continue 3 months.? After mouse is put to death, musculus quadriceps is fully cut off, is rapidly frozen and grinds.Soluble protein is extracted from musculature, and The amount of AMPK is measured by immunoassay (ELISA).
Compared with the control group for not receiving collagenic hydrolysate, the amount of AMPK increases 1.5-2 times.
4. the external influence that collagenic hydrolysate generates NADH
From the low energy form NAD of nicotinamide adenine dinucleotide+Form rich form of energy NADH+H+It is equivalent to generate The energy of ATP form.Therefore it is the active indirect measurement of myocyte's Mitochondria.
For this test, human muscle cell is cultivated 6 days in the culture medium comprising 0.5mg/ml collagenic hydrolysate.? After removing culture medium, triglycerides is extracted, and is measured with the help of enzyme glycerokinase and glycerol-3-phosphate dehydrogenase sweet With NADH+H in oily three esters and glycerol+The energy of form release.
Compared with the control without collagenic hydrolysate, about 2 times of the amount increase of NADH.
5. increasing mitochondria density in vivo in rats
In preclinical study, it can prove in Rat Skeletal muscle system caused by as applying different collagenic hydrolysates Mitochondria density dramatically increases (that is, the increase of mitochondria number and/or increase of mitochondria size).
The research pairThe male rat of IGS system (Charles River Laboratories, Sulzfeld) It carries out, it is 300-400g that the rat, which is 64 day age weight when studying and starting,.Test group and control group respectively include six animals.
When studying beginning (t=0), the quadriceps muscle of thigh biopsy of every rat is obtained by fine needle aspiration.In surrounding Time in, the animal of test group then receives the day of the respective collagenic hydrolysate (seeing below) of per kilogram Current body mass 200mg Dosage (daily dose for being equivalent to the 15g for the people of 75kg weight).Collagenic hydrolysate is dissolved in the concentration of 20mg/ml suitable It is applied in the tap water of amount and by stomach tube.The animal of control group respectively receive equivalent do not include collagenic hydrolysate originally Water.
Other than above-mentioned collagenic hydrolysate A, the collagen water of double-layer fur gelatin has been used in other test group Solve product B, average molecular weight 2000Da；With the collagenic hydrolysate C of double-layer fur gelatin, average molecular weight 3500Da, It is all to be produced by enzymatic hydrolysis under all situations.The molecular weight distribution of all three hydrolysates is shown in the following table 2:
Table 2: with the molecular weight distribution of the weight % collagenic hydrolysate indicated
Fraction Hydrolysate A Hydrolysate B Hydrolysate C
>7500Da <10 <3 4-14
3500–7500Da 20-30 10-20 18-25
1500–3500Da 30-33 25-32 30-38
500–1500Da 25-38 40-50 28-36
100–500Da <5 <15 <7
Average molecular weight 3000Da 2000Da 3500Da
After (t=4 weeks) terminates in the test period, all rats are put to death, and obtain stock four again by fine needle aspiration Head Muscle biospy tissue.In surrounding, rat body weight averagely increases about 30%, does not have significance difference between test group and control group It is different.
In order to determine mitochondria density, as described in the literature with before and after the tem study test period (referring to A.Glauert and P.Lewis: prepared by the biological sample for transmission electron microscope for the biopsy of acquirement (Biological Specimen Preparation for Transmission Electron Microscopy), Princeton Legacy Library,2014).It in all situations, is 15.17 by the individual size of muscle biopsy tissue x 15.17μm(230μm2) surface portion digitlization and semi-quantitative assessment.Herein, using 10 from each biopsy Average mitochondrial surface product of a independent sample measurement as total surface area ratio.It can be from the clearly visible of the inner membrance with ridge Characteristic structural positions mitochondria.
The following table 3 show the mitochondria density in the test group animal using collagenic hydrolysate A development (μm2Line grain Body/230 μm2Total surface area):
Table 3: the development of test group A at any time
Rat number Test group A, t=0 Test group A, t=4w
1 9.82 11.97
2 10.36 17.44
3 6.84 12.36
4 8.15 17.46
5 8.03 15.61
6 6.18 13.29
Average value 8.23 14.69
Standard deviation ±1.63 ±2.48
The result shows that application collagenic hydrolysate A surrounding causes the obviously increase of mitochondria density, it is average to increase 78.5%, have statistical significance (p=0.001).
Mitochondria density comparison between test group and control group by applying collagenic hydrolysate A, B and C also turns out Similar discovery.In all cases, the result after 4 weeks is shown in the following table 4:
Table 4: test group A, B and C are compared with control group
In test group, mitochondria density average specific control group high by 56.6% (A), 59.5% (B) and 90.4% (C), knot Fruit equally has statistical significance (p=0.001).For all test groups, the Cohen's of the measurement as effect size D value is both greater than 2.5, therefore all shows very specific effect in each case.
In short, this research provides tangible proof, it was demonstrated that application collagenic hydrolysate causes in myocyte Mitochondria density dramatically increase and thus mitochondria activity is increase accordingly.This effect can with separate sources (pig and Ox) and the collagenic hydrolysate of molecular weight distribution confirm.

Claims (18)

1. collagenic hydrolysate is used to improve the purposes of endurance performance by increasing mitochondria activity.
2. collagenic hydrolysate is used to stimulate lipid catabolism by increasing mitochondria activity, the use especially lost weight On the way.
3. the purposes of claims 1 or 2, wherein the purposes is non-therapeutic use, especially beautifying use.
4. the purposes of claims 1 or 2, wherein the purposes is to be characterized in that mitochondria activity drops for preventing and/or treating It is low, especially it is characterized in that the therapeutic use of the pathological conditions of endurance performance decline and/or weight gain.
5. the purposes of claim 4, wherein the pathological conditions are selected from obesity, cardiovascular disease, cardiac arrhythmia, heart function Incomplete, hypotony, hypertension, metabolic disorder, diabetes, metabolic syndrome, abrasive grit cellulous anemia, kidney and liver function barrier Hinder, neuropathy, incoordination, epileptic attack, dementia, Alzheimer's disease, autism, depression, chronic fatigue syndrome, Parkinson's disease, motor neuron disease, multiple sclerosis, apoplexy sample symptom, migraine, myoclonia, paralysis, neuralgia, the pain sensation Allergy, hyperesthesia, dysphagia, vomiting, constipation, diarrhea, optic nerve fiber and the denaturation of retina, nystagmus, eyelid Sagging, yctalopia, hearing loss, deafness and inner ear disorders.
6. the purposes of any one of preceding claims, wherein collagenic hydrolysate is applied through enteron aisle, is especially administered orally.
7. the purposes of claim 6, wherein collagenic hydrolysate is in the form of nutritional supplement, particularly with solution or powder Form application.
8. the purposes of claim 7, wherein the nutritional supplement does not include other albumen other than collagenic hydrolysate Matter or protein hydrolysate.
9. the purposes of claim 7 or 8, wherein the nutritional supplement does not include other other than collagenic hydrolysate Physiologically active component.
10. the purposes of any one of claim 6-9, wherein collagenic hydrolysate is with daily 1-40g, preferably daily 2.5-30g, more It is preferred that the amount of daily 10-25g, especially daily 12.5-20g are applied.
11. the purposes of any one of claim 1-8 or claim 10, wherein by collagenic hydrolysate and one or more components Combination, described group is selected from vitamin C, vitamin B, D, E and K series, conjugated linoleic acid, caffeine and its derivative, melon drawing Receive extract, green-tea extract, Epigallo-catechin gallate (EGCG), creatine, L-BETAIN, L-citrulline, L-arginine, Alpha-lipoic acid, N-acetylcystein, NADH, D-ribose, magnesium aminosuccinate, antioxidant such as anthocyanidin, carotenoid, class Flavones, resveratrol, glutathione, superoxide dismutase and xanthone such as mangiferin, minerals for example iron, magnesium, calcium, zinc, Selenium and phosphorus and other oroteins, hydrolysate or peptide such as soybean, wheat or lactalbumin.
12. the purposes of any one of claim 1-8, claim 10 or claim 11, wherein by collagenic hydrolysate with it is excellent The 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone and/or panthenol that choosing is applied with the amount of daily 50-100mg combine, and/or combine with pyrroloquinoline quinone (PQQ).
13. the purposes of any one of preceding claims, the wherein application with endurance training or altitutde training phase of collagenic hydrolysate Combination.
14. the purposes of any one of claim 1-12, wherein the application of collagenic hydrolysate is instructed on endurance training, plateau It carries out in the case where experienced or muscular training, is especially combined with normal body movement.
15. the purposes of any one of preceding claims, wherein the average molecular weight of the collagenic hydrolysate is 200- 25000Da, preferably 1000-6000Da, more preferable 1200-4000Da, even more preferably 1500-3500Da, especially 2800- 3300Da。
16. the purposes of any one of preceding claims, wherein collagenic hydrolysate by the inclusion of the starting material of collagen enzymatic Hydrolysis is to produce.
17. the purposes of claim 16, wherein described includes that the starting material of collagen is selected from vertebrate, preferably mammal Skin or bone, and the skin of especially ox or pig.
18. the purposes of any one of claim 1-15, wherein collagenic hydrolysate is produced by recombinant gene expression.
CN201780053530.4A 2016-08-30 2017-08-23 Collagenic hydrolysate is used to improve the purposes of endurance performance and stimulation lipid catabolism Pending CN109715197A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102016116160 2016-08-30
DE102016116160.8 2016-08-30
DE102017102873.0A DE102017102873A1 (en) 2016-08-30 2017-02-14 Use of collagen hydrolyzate to improve endurance and stimulate fat loss
DE102017102873.0 2017-02-14
PCT/EP2017/071184 WO2018041684A1 (en) 2016-08-30 2017-08-23 Use of collagen hydrolysate for improving endurance performance and for stimulating lipocatabolism

Publications (1)

Publication Number Publication Date
CN109715197A true CN109715197A (en) 2019-05-03

Family

ID=68039643

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780053530.4A Pending CN109715197A (en) 2016-08-30 2017-08-23 Collagenic hydrolysate is used to improve the purposes of endurance performance and stimulation lipid catabolism

Country Status (10)

Country Link
EP (1) EP3506929A1 (en)
KR (1) KR20190042006A (en)
CN (1) CN109715197A (en)
AU (1) AU2017320520A1 (en)
BR (1) BR112019002725A2 (en)
CA (1) CA3035281A1 (en)
CL (1) CL2019000529A1 (en)
MX (1) MX2019002335A (en)
SG (1) SG11201901043RA (en)
WO (1) WO2018041684A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111759828A (en) * 2019-04-01 2020-10-13 许悦郎 Composition and application thereof in treating and/or preventing dementia

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
DE102018104590A1 (en) * 2018-02-28 2019-08-29 Gelita Ag Nutraceutical or pharmaceutical composition
CN108685971A (en) * 2018-06-12 2018-10-23 泓博元生命科技（深圳）有限公司 A kind of Weight reducing compound and its preparation method and application
US11998654B2 (en) 2018-07-12 2024-06-04 Bard Shannon Limited Securing implants and medical devices
DE102018120183A1 (en) * 2018-08-20 2020-02-20 Gelita Ag Beverage and solid mixture for its manufacture
DE102018120420A1 (en) * 2018-08-22 2020-02-27 Gelita Ag protein bars
DE102019207859A1 (en) * 2018-12-21 2020-06-25 Gelita Ag Synthetic and recombinantly produced collagen peptides with biological effectiveness
KR20210151930A (en) 2019-04-12 2021-12-14 젤터, 인코포레이티드 Recombinant elastin and preparation thereof
JP2021038147A (en) * 2019-08-30 2021-03-11 国立大学法人 鹿児島大学 Mitochondrial biosynthesis promoter
GB2610313B (en) 2020-01-24 2024-07-03 Geltor Inc Animal-free dietary collagen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002255846A (en) * 2001-02-26 2002-09-11 Sunstar Inc Oral composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102210855A (en) * 2011-04-20 2011-10-12 中国海洋大学 Complex of marine oligosaccharides and collagen peptides, preparation method thereof and application thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002255846A (en) * 2001-02-26 2002-09-11 Sunstar Inc Oral composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
娄文娟: "酶解猪皮明胶制备抗疲劳肽及其功效研究", 《中国优秀硕士学位论文全文数据库 工程科技I辑》, no. 2, pages 1 - 67 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111759828A (en) * 2019-04-01 2020-10-13 许悦郎 Composition and application thereof in treating and/or preventing dementia

Also Published As

Publication number Publication date
CA3035281A1 (en) 2018-03-08
CL2019000529A1 (en) 2019-07-26
BR112019002725A2 (en) 2019-05-14
KR20190042006A (en) 2019-04-23
AU2017320520A1 (en) 2019-03-21
SG11201901043RA (en) 2019-03-28
EP3506929A1 (en) 2019-07-10
MX2019002335A (en) 2019-05-16
WO2018041684A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
CN109715197A (en) Collagenic hydrolysate is used to improve the purposes of endurance performance and stimulation lipid catabolism
Pellerin Food for thought: the importance of glucose and other energy substrates for sustaining brain function under varying levels of activity
US12023369B2 (en) Use of collagen hydrolysate for improving endurance performance and for stimulating lipid catabolism
CN108244252A (en) Probiotics multielement protein powder and preparation method thereof
CN1711859A (en) Fermented milk sheets with auxin
TWI830696B (en) Compositions for inhibiting muscle fiber degeneration
CN1736220A (en) Anti-fatigue yoghurt tablet
CN112206237A (en) Anti-aging composition containing zinc taurate, preparation method and application thereof
JP2016505615A (en) Synergistic health supplement composition for enhancing physical ability and energy level
CN106880050A (en) A kind of five rings mutually promotees medicine food of micro- raw group regulation mood and preparation method thereof
CN109699756A (en) Use of balsam pear seed oil for producing a composition for simulating sports effects
Liu et al. Pyrroloquinoline quinone protects against exercise‐induced fatigue and oxidative damage via improving mitochondrial function in mice
WO2019166418A1 (en) Nutraceutical or pharmaceutical composition
CN106665337A (en) Rice breeding method
CN104152401B (en) A kind of CHMM1 culture mediums suitable for Chinese&#39;s epidermal melanophore in vitro culture
CN105050428A (en) Food supplement for people with down syndrome, autism spectrum disorder and/or attention deficit disorder with or without hyperactivity
CN105963327A (en) Vitamin K2 composition for prevention and treatment of liver function impairment
Zaborova et al. Metabolic and body composition changes in ice hockey players using an ergogenic drug (Cytoflavin)
DE102014017455A1 (en) Creatine-containing nutritional supplement to improve sleep
Sarma et al. Fortification methods of coenzyme Q10 in yogurt and its health functionality—a review
JP2021151223A (en) Myokine producing promotor, muscle output promotor, and myoblast differentiation promotor
CN105360798A (en) Maca formula capable of strengthening tolerance and explosive force and preparation method thereof
KR102599279B1 (en) Manufacturing method of herbal fermented eye drops
JP2019182753A (en) Endo180 production promoter
CN106962704A (en) Amino acid beverage composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination